ROCHESTER, N.Y., Aug. 16, 2012 /PRNewswire/ -- Lucid, Inc. announced today that, effective immediately, it is operating under a new company name, Caliber Imaging & Diagnostics, Inc., or Caliber ID. The new name reflects the company's commitment to innovating and delivering the highest caliber identification tools for accurate, rapid diagnosis to assist in the fight against skin cancer and other diseases.
Caliber ID has created an entirely new class of tools enabling physicians to image and diagnose skin disease in real time without a biopsy. These devices using Caliber ID's reflectance confocal microscopy (RCM) technology allow physicians to detect and diagnose skin disease, including basal cell carcinoma, melanoma, and inflammatory and pigmentary disorders. Caliber ID's RCM technology offers physicians the option to non-invasively diagnose, monitor and follow-up the non-invasive treatment of basal cell carcinoma, the most commonly diagnosed cancer in mankind, and includes the capacity to visualize the margins of the disease prior to surgery, improving patient outcomes.
"This technology is clearly a clinically-relevant diagnostic tool," notes Dr. Martin C. Mihm Jr., Associate Physician at Brigham and Women's Hospital, Clinical Professor of Pathology (Dermatology) at Harvard Medical School and chair of the Caliber ID scientific advisory board. "The clinical data indicates that this suite of technologies can substantially reduce the need to biopsy healthy tissue by giving physicians the ability to noninvasively image and diagnose skin cancers and other skin disease. In the hands of an experienced confocal user, resolution and accuracy is comparable to that of traditional histology."
The Company has developed an integrated platform of tools, including the Caliber ID VivaScope® 1500 and VivaScope® 3000 imagers along with Caliber ID's telepathology service that can be used by doctors, surgeons, and research laboratories. Its tools are already in use by doctors and researchers in major academic hospitals including Memorial Sloan Kettering (New York, NY), Brigham and Women's Hospital (Boston, MA), the Charite Hospital in Berlin (GERMANY) and the Melanoma Institute Australia (Sydney, AUSTRALIA).
About Caliber ID
Caliber ID's platform of products offer increased productivity from the doctor's office to the surgeon's operating room. Today, the future of skin cancer diagnosis is here: an integrated platform of tools and technology for accurate diagnoses quickly and routinely. Caliber ID products provide precise accuracy, consistent reliability, and online backup that all combine to lead to life-saving early diagnosis. Wherever you are in the continuum of skin imaging and diagnosis, this is not just best in class. This is a new class. For more information about Caliber ID and its products, please visit www.caliberid.com
VivaScope® is a registered trademarks of Caliber ID.
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed with the SEC.